- 20 biggest launches of 2012 were led by Kalydeco and Xtandi
Vertex Pharmaceuticals' Kalydeco, or ivacaftor, topped Genetic Engineering & Biotechnology News' list of best-selling drugs that were approved and commercialized last year based on 2012 sales figures. Kalydeco generated sales of $171.6 million. Medivation and Astellas Pharma's Xtandi, or enzalutamide, came in second with $71.5 million, followed by Pfizer's Inlyta, or axitinib, with $70.1 million. Rounding out the top five were Onyx Pharmaceuticals' Kyprolis, or carfilzomib, and Roche Holding's Perjeta, or pertuzumab. The list includes the dates of approval in the U.S. and/or Europe. Genetic Engineering & Biotechnology News/Insight & Intelligence (4/8)        | Experience makes the difference:
BioPharma Solutions, a business unit of Baxter, can help support your commercialization objectives by providing scientific expertise, sterile contract manufacturing solutions, parenteral delivery systems, and more. Talk to us in April at BIO in Chicago or Interphex in NY. | |
| Health Care & Policy |  |  | | - Spectrum's chemo-induced neutropenia drug enters midstage trial
Spectrum Pharmaceuticals initiated a midstage trial to assess the efficacy of its experimental long-acting granulocyte colony stimulating factor drug SPI-2012, in comparison with pegfilgrastim, in patients with chemotherapy-induced neutropenia. The main goal of the trial is to evaluate the effect of doses on the average length of severe neutropenia in breast cancer patients who are candidates for chemotherapy. Pharmaceutical Business Review Online (4/9) - Researchers create mutated antibodies to fight dengue
Massachusetts Institute of Technology researchers developed antibodies that are able to bind better to all four serotypes of the dengue virus, a possible step toward effective vaccines, according to a study in the Proceedings of the National Academy of Sciences. The researchers used an antibody called 4E11, and a mutated antibody allowed significantly improved binding to two serotypes and lesser improvements for the other two. Yahoo/Asian News International (4/9) | Company & Financial News | | | | | Global Developments | | | | - Japanese drugmakers, government team up to fight disease
Japan's government has joined the Bill & Melinda Gates Foundation as well as drugmakers Astellas, Eisai, Daiichi-Sankyo, Shionogi and Takeda to form the Global Health Innovative Technology fund to develop diagnostic tests, drugs and vaccines to fight disease in developing countries. The group will collaborate on research with significant impact, says Dr. Kiyoshi Kurokawa, the fund's chairman. The Japan Daily Press (4/8) | Food & Agriculture | | | | | Industrial & Environmental | | | | - Abengoa switches on demo waste-to-fuel plant in Spain
Abengoa Bioenergy's demonstration-scale waste-to-fuel plant in Spain is up and running. The facility will have the ability to produce 396,258 gallons of biofuel from 25,000 metric tons of biomass per year. The company is developing a commercial-scale biorefinery in Hugoton, Kan., which is due to go online by the end of the year. EthanolProducer.com (4/9) | News from BIO | | | | - April 2013 BIO therapeutic newsletters
The BIO Emerging Companies Section Policy Team has compiled the latest news to keep you informed on the action in Washington with respect to the disease category on which your company is focused. Topics covered comprise: Allergy/Infectious Disease/Antiviral; Cardiology/Pulmonology/Blood; Nephrology/Endocrinology/Metabolism/Gastroenterology; Neurology/CNS; Oncology; and Rheumatology/Anesthesia/Inflammation/Pain. BIO has attempted to include updates from biotech stakeholders around Washington, including Congress, FDA, NIH and patient organizations. Access our April 2013 Therapeutic Newsletters. Should you have any comments or questions, please contact Charles Crain.
| SmartQuote | | | |  | Our political institutions work remarkably well. They are designed to clang against each other. The noise is democracy at work."
--Michael Novak,
American philosopher, journalist, novelist and diplomat  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Tuesday, April 09, 2013
- Monday, April 08, 2013
- Friday, April 05, 2013
- Thursday, April 04, 2013
- Wednesday, April 03, 2013
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2013 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment